Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...
The lawsuit, filed by the Outsourcing Facilities Association , FarmaKeio Custom Compounding and North American Custom Laboratories in the U.S. District Court for the Northern District of Texas, argues ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...
The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...
Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Ozempic and its contemporaries are the new craze. But would you believe it when we say that these weight-loss drugs would be ...
Hims & Hers faces new headwinds in its weight management segment with the Food and Drug Administration ending the shortage of ...